In Silico Design of Optimal Ratio for Co-Administration of Pramlintide and Insulin in Type 1 Diabetes

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Diabetes Technology & Therapeutics

• Publication date

  2013-09-19

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1089/dia.2013.0054PMID 23865841PMCID PMC3781117
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The T1D Exchange clinic registry.

  2012cited by this paper
• Simultaneous Use of Two External Subcutaneous Pumps Delivering Insulin and SYMLIN: Use of a Double-Pump System

  2012cited by this paper
• Artificial Pancreas: Past, Present, Future

  2011cited by this paper
• Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes.

  2010cited by this paper
• Diabetes: Models, Signals, and Control

  2010cited by this paper
• Continuous subcutaneous pramlintide infusion therapy in patients with type 1 diabetes: observations from a pilot study.

  2009cited by this paper
• Twenty-four-hour simultaneous subcutaneous Basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia.

  2009cited by this paper
• Continuous Glucose Monitoring and Intensive Treatment of Type 1 Diabetes

  2009cited by this paper
• Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005).

  2009cited by this paper
• In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes

  2009cited by this paper
• Impaired Hyperglycemia-Induced Delay in Gastric Emptying in Patients With Type 1 Diabetes Deficient for Islet Amyloid Polypeptide

  2008influential reference
• Evaluating the Efficacy of Closed-Loop Glucose Regulation via Control-Variability Grid Analysis

  2008influential reference
• Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach.

  2008cited by this paper
• Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans.

  2008cited by this paper
• Continuous glucose monitoring and intensive treatment of type 1 diabetes.

  2008cited by this paper
• Meal Simulation Model of the Glucose-Insulin System

  2007cited by this paper
• GIM, Simulation Software of Meal Glucose—Insulin Model

  2007cited by this paper
• A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes

  2007cited by this paper
• Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC)

  2007cited by this paper
• Pramlintide as An Adjunct to Insulin in Patients with Type 2 Diabetes in A Clinical Practice Setting Reduced A1C, Postprandial Glucose Excursions, And Weight

  2007cited by this paper
• Glycemic and Risk Factor Control in Type 1 Diabetes

  2007cited by this paper
• Pramlintide in the Management of Insulin-Using Patients with Type 2 and Type 1 Diabetes

  2006cited by this paper
• Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes

  2005cited by this paper
• Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.

  2003cited by this paper
• Validation of the archimedes diabetes model.

  2003cited by this paper
• Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.

  2003cited by this paper
• Archimedes: a trial-validated model of diabetes.

  2003cited by this paper
• ADMET in silico modelling: towards prediction paradise?

  2003cited by this paper
• Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus

  2002cited by this paper
• The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.

  2002cited by this paper
• Clinical Implications of Amylin and Amylin Deficiency

  1999cited by this paper
• The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM

  1998cited by this paper
• The Diabetes Control and Complications Trial

  1998cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Quantitative estimation of insulin sensitivity.

  1979cited by this paper
• Die theoretischen Grundlagen und die praktische Verwendbarkeit der gerichtlich-medizinischen Alkoholbestimmung

  1932cited by this paper

• In silico Digital Twins of Bone Metastasis Enable Investigation of Tumor Progression and Therapy Response.

  2025cites this paper
• In silico evaluation of pramlintide dosing algorithms in artificial pancreas systems

  2025cites this paper
• Various Approaches and Future Prospective for Therapies for Diabetes: A Review

  2024cites this paper
• A model of subcutaneous pramlintide pharmacokinetics and its effect on gastric emptying: Proof-of-concept based on populational data

  2023cites this paper
• Artificial pancreas systems: experiences from concept to commercialisation

  2022cites this paper
• Ultra-fast insulin-pramlintide co-formulation for improved glucose management in diabetic rats

  2021cites this paper
• Ultra‐Fast Insulin–Pramlintide Co‐Formulation for Improved Glucose Management in Diabetic Rats

  2021cites this paper
• Minimal and Maximal Models to Quantitate Glucose Metabolism: Tools to Measure, to Simulate and to Run in Silico Clinical Trials

  2021cites this paper
• In silico deceased donor intervention research: A potential accelerant for progress

  2021cites this paper
• The Amylin Circuit-Breaker: Restoring Glucagon Counterregulation in T1D

  2020cites this paper
• ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes

  2020cites this paper
• Physiological models for artificial pancreas development

  2019cites this paper
• Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study

  2018cites this paper
• Glucagon treatment in type 1 diabetes -with focus on restoring plasma glucose during mild hypoglycemia
.

  2018cites this paper
• IAPP and type 1 diabetes: implications for immunity, metabolism and islet transplants.

  2018cites this paper
• Clinical Impact of Blood Glucose Monitoring Accuracy: An In-Silico Study

  2017cites this paper
• Future of Automated Insulin Delivery Systems

  2017cites this paper
• Comparison of bioartificial and artificial pancreatic transplantation as promising therapies for Type I Diabetes Mellitus

  2016cites this paper
• Fixed ratio dosing of pramlintide with regular insulin before a standard meal in patients with type 1 diabetes

  2015cites this paper
• Closed-Loop Artificial Pancreas Systems: Physiological Input to Enhance Next-Generation Devices

  2014cites this paper
• A Model of Glucose-Insulin-Pramlintide Pharmacokinetics and Pharmacodynamics in Type I Diabetes

  2014cites this paper
• Effects of delayed gastric emptying on postprandial glucose kinetics, insulin sensitivity, and β-cell function.

  2014cites this paper
• Distributed aspects of the artificial pancreas

  2013cites this paper
• Annals of the New York Academy of Sciences the Artificial Pancreas: Current Status and Future Prospects in the Management of Diabetes

  year unknowncites this paper